Sun Pharma Share Price
(SUNPHARMA)
Check the latest share price of Sun Pharma, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.
as on 04:01PM, 02 May 2025
NSE
Sun Pharma Performance
Get real-time share price information, day’s high and low, historical returns and market stats.
Day's Low
Day's High
₹1,813.8Day's Price Range₹1,851.252 Week's Low
52 Week's High
₹1,377.252-Week Price Range₹1,960.35
| Returns % | |
| 1 Month Return | + 3.36 % |
| 3 Month Return | + 5.1 % |
| 1 Year Return | + 21.06 % |
| Market Stats | |
| Previous Close | ₹1,832.30 |
| Open | ₹1,832.30 |
| Volume | 23.11L |
| Upper Circuit | ₹2,015.50 |
| Lower Circuit | ₹1,649.10 |
| Market Cap | ₹4,38,934.34Cr |
Sun Pharma Fundamentals & Key Indicators
Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.
Market Cap
₹4,38,934.34 Cr
Return on Equity (ROE)
12.05
PE Ratio (TTM)
38.35
Return on capital employed (ROCE)
12.22
Beta (LTM)
0.62
P/B Ratio
16.41
Dividend Yield
0.83
PEG Ratio
3.62
EPS (TTM)
40.21
Sector
Pharmaceuticals
Technical Analysis
Bullish
View Technical Analysis
How to invest in Sun Pharma
Investing in Sun Pharma is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Sun Pharma or SUNPHARMA on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Sun Pharma or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Sun Pharma with just a few clicks!
Sun Pharma Valuation
Track how the P/E of Sun Pharma has moved over time to understand valuation trends.
Sun Pharma in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (38.35x)
May 2, 2025
Industry (54.34x)
May 2, 2025
Highest (184.63x)
August 28, 2020
Today’s Price to Earnings Ratio: 38.35x
Analysts Recommendation on Sun Pharma
Get updated buy, sell, and hold recommendations by analysts on Sun Pharma.
based on 37 analysts
81.08%
Buy
10.81%
Hold
8.11%
Sell
81.08% of analysts recommend a 'BUY' rating for Sun Pharma. Average target price of ₹2047.89
Source: S&P Global Market Intelligence
Analysts Forecast on Sun Pharma
Get share price movements and forecasts by analysts on Sun Pharma.
Sun Pharma price forecast by 37 analysts
Upside of11.94%
High
₹2450
Target
₹2047.89
Low
₹1500
Sun Pharma target price ₹2047.89, a slight upside of 11.94% compared to current price of ₹1829.4. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharma revenue growth forecast
Expected growth rate Q1, FY2027:32.23%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharma EPS growth forecast
EPS estimate Q1, FY2027:56.55%
Forecast
Actual
Source: S&P Global Market Intelligence
Sun Pharma Financials
Get the annual and quarterly financial summary of Sun Pharma, including revenue, profit, loss and more.
Sun Pharma Index Inclusions
Sun Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Sun Pharma.
Sun Pharmaceutical Industries Ltd Earnings Results
Sun Pharmaceutical Industries Ltd’s net profit jumped 15.04% since last year same period to ₹2,903.38Cr in the Q3 2024-2025. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated -4.5% fall in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceutical Industries Ltd Dividends January,2025
In the quarter ending December 2024, Sun Pharmaceutical Industries Ltd has declared dividend of ₹10.50 - translating a dividend yield of 1.31%.
Read More about Dividends
Sun Pharma Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Sun Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 17.96% | 0.00 | |
| Mutual Funds | 12.21% | 0.00 | |
| Retail Investors | 8.87% | 0.00 | |
| Others | 6.48% | 0.00 |
Sun Pharma vs Peers
Compare market cap, revenue, PE, and other key metrics of Sun Pharma with its industry peers.
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,38,934.34 Cr | 58.61% | 0.68 | ₹9,648 Cr | ₹48,496 Cr | |
| HOLD | ₹1,62,042.02 Cr | 33.38% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,10,165.81 Cr | 34.8% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹38,287.13 Cr | -2.18% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹23,123.56 Cr | -4.57% | 0.50 | ₹772 Cr | ₹5,664 Cr |
Sun Pharma News & Key Events
Latest news and events at one place to help you take investing decisions in Sun Pharma.
Sun Pharma Leadership Change and Buy Recommendations - 02 May, 2025
Sun Pharmaceutical Industries Ltd has elevated Bhaskar Dharival to GM and Head of HR & Administration. Analysts recommend buying the stock, targeting Rs 1,925.Sun Pharma Shows Bullish Momentum with Buy Recommendation - 29 Apr, 2025
Sun Pharma's share price has broken out of a double bottom pattern, indicating bullish momentum. Analysts recommend buying shares with a target price of ₹1,950 and a stop loss at ₹1,785.Sun Pharma Reports Positive Osteoarthritis Drug Trial Results - 24 Apr, 2025
Sun Pharmaceutical Industries and Moebius Medical announced positive results for MM-II, a novel osteoarthritis treatment, showing significant pain relief and a favorable safety profile. This development may provide a promising alternative to existing treatments.Sun Pharma Anticipates Strong US Market Growth - 23 Apr, 2025
Sun Pharmaceutical Industries is projected to deliver a 12% year-over-year growth in the US market, primarily due to the success of its specialty portfolio.Sun Pharma Shares Rise with Buy Recommendation - 20 Apr, 2025
Sun Pharmaceutical Industries Ltd shares closed at Rs.1,757.00, up 3.77%. Emkay Global recommends a Buy with a target price of Rs.2,400, suggesting a 40% upside.Sun Pharma Faces Recall Amid Regulatory Challenges - 14 Apr, 2025
Sun Pharmaceutical Industries is recalling several medicines from the US market due to manufacturing-related problems, contributing to a challenging environment for the company amid strong competition and regulatory pressures.Sun Pharma Faces Recall Amid Stock Recovery - 13 Apr, 2025
Sun Pharmaceutical Industries has seen a recovery in its stock, regaining nearly half of its earlier losses. However, it is also recalling 13,700 bottles of Gabapentin capsules due to cross-contamination concerns, which may impact investor sentiment.Sun Pharma Gains Court Approval for Leqselvi Launch - 10 Apr, 2025
Sun Pharmaceutical Industries received a favorable ruling from the U.S. Court of Appeals, lifting the injunction on Leqselvi's launch, projected to boost sales significantly in FY26 and FY27.Sun Pharma Faces Challenges from US Tariff Announcement - 09 Apr, 2025
Sun Pharmaceutical Industries Ltd is expected to face challenges due to upcoming US tariffs on pharmaceutical imports, leading to a negative trading outlook and lower stock performance.Sun Pharma Launches New Drug Amid Market Challenges - 07 Apr, 2025
Sun Pharmaceutical Industries launched FEXUCLUE for Erosive Esophagitis, demonstrating high efficacy in trials. However, shares fell 3.47% as the Nifty Pharma index hit a 10-month low.Sun Pharma Faces Tariff Concerns Amid Growth Prospects - 04 Apr, 2025
Sun Pharma shares declined due to tariff concerns after Trump's announcement, but the company is projected to achieve significant sales growth in Q4FY25, maintaining a positive outlook from analysts.Sun Pharma Shares Surge on Tariff Exemption News - 03 Apr, 2025
On April 3, 2025, Sun Pharmaceutical Industries saw its shares rise over 5% after the U.S. confirmed that Indian pharmaceutical exports would not face new tariffs. This decision is viewed positively by brokerages, highlighting Sun Pharma's resilience amid potential tariff disruptions.
Insights on Sun Pharmaceutical Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 3 months, SUNPHARMA stock has moved up by 5.1%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 12.58K Cr → 14.14K Cr (in ₹), with an average increase of 3.8% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 141.8% return, outperforming this stock by 38.8%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 54.5% return, outperforming this stock by 33.4%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 12.24% to 12.21% in Mar 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 18.05% to 17.96% in Mar 2025 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 3.04K Cr → 2.90K Cr (in ₹), with an average decrease of 4.5% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 8.92% to 8.87% in Mar 2025 quarter
About Sun Pharma
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Revenue: ₹13,436.94Cr as on December 2024 (Q4 24)
Net Profit: ₹2,917.54Cr as on December 2024 (Q4 24)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharmaceutical Industries Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Indian Mutual Funds that own Sun Pharma
Check out the Mutual Funds with significant holdings in Sun Pharma.
FAQs
What is Sun Pharmaceutical Industries Ltd price today?
Sun Pharmaceutical Industries Ltd share price today stands at ₹1829.4, Open: ₹1832.3, Previous Close: ₹1832.3, High: ₹1851.2, Low: ₹1813.8, 52 Week High: ₹1960.35, 52 Week Low: ₹1377.2.
How to Buy Sun Pharmaceutical Industries Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Sun Pharmaceutical Industries Ltd shares
What are today's traded volumes of Sun Pharmaceutical Industries Ltd?
Today's traded volume of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is 23.11L.
What is today's market capitalisation of Sun Pharmaceutical Industries Ltd?
Today's market capitalisation of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is ₹4,38,934.34 Cr.
What is the 52 Week High and Low Range of Sun Pharmaceutical Industries Ltd?
How much percentage Sun Pharmaceutical Industries Ltd is down from its 52 Week High?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1829.4. It is down -6.68% from its 52 Week High price of ₹1960.35
How much percentage Sun Pharmaceutical Industries Ltd is up from its 52 Week low?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1829.4. It is up 32.83% from its 52 Week Low price of ₹1377.2